Immunocore Holdings (IMCR) Return on Sales (2021 - 2026)

Immunocore Holdings (IMCR) has reported Return on Sales for 6 consecutive years, with 0.0% the latest figure, recorded in Q1 2026.

• Quarterly Return on Sales changed 0.0% year-over-year to 0.0% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.0% (changed 0.0% YoY) and the FY2025 annual result came in at 0.0%, changed 0.0% from the prior year.
• Return on Sales advanced to 0.0% in Q1 2026 per IMCR's latest filing, from 0.0% in the prior quarter.
• Over the last five years, Return on Sales for IMCR reached as high as 0.0% in Q3 2022 and fell as low as 0.01% in Q4 2022.
• A 5-year average of 0.0% and a median of 0.0% in 2023 frame the typical range for Return on Sales.
• Annual changes were most pronounced in 2022 — Return on Sales increased 5 bps — and 2023, when it changed 0 bps.
• Year by year, Return on Sales stood at 0.01% in 2022, then soared by 47 bps to 0.0% in 2023, then slipped by 1 bps to 0.0% in 2024, then slipped by 2 bps to 0.0% in 2025, then surged by 142 bps to 0.0% in 2026.
• According to Business Quant data, Return on Sales over the past three periods registered 0.0%, 0.0%, and 0.0% for Q1 2026, Q4 2025, and Q3 2025 respectively.